Study guide

4.3 Pharmacokinetic Changes with Aging

ANCC Gerontological Nursing Certification GERO-BC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the GERO-BC Exam 1.2 Eligibility, Fees, Scoring & Testing 1.3 How to Study for GERO-BC

2 Assessment Tools: Physical & Psychosocial

2.1 Fall, Depression & Pressure-Injury Risk Tools 2.2 Cognitive Assessment Tools (MMSE, MoCA, SLUMS, CAM) 2.3 Functional (ADL/IADL) & Pain Assessment

3 Social Determinants & Care Context

3.1 Social Determinants of Health in Aging 3.2 Caregiver & Support-System Assessment 3.3 Living Environment & Access Barriers

4 Pharmacotherapy Assessment

4.1 Polypharmacy Identification & Medication Review 4.2 Drug Interactions in Older Adults 4.3 Pharmacokinetic Changes with Aging

5 Aging Physiology & Clinical Findings

5.1 Sensory & Neurological Aging Changes 5.2 Circulatory & Cardiopulmonary Aging 5.3 Distinguishing Normal Aging from Pathology

6 Risk Factor Identification

6.1 Cognitive Impairment Risk Recognition 6.2 Non-Adherence Risk Factors 6.3 Elder Abuse & Neglect Screening

7 Evidence-Based Interventions

7.1 Evidence-Based Interventions & Expected Outcomes 7.2 Chronic Disease Management in Older Adults 7.3 Delirium Prevention & Dementia Care 7.4 Depression Care & Palliative/Hospice Care

8 Medications, Beers Criteria & Contraindications

8.1 Beers Criteria Essentials 8.2 Dosage & Route Modifications for Older Adults 8.3 Food, Drug & Herbal Contraindications

9 Care Planning & Prioritization

9.1 Nursing Diagnosis & Problem-List Evaluation 9.2 Person-Centered Care Planning 9.3 Outcome Evaluation & Plan Revision

10 Safety & Therapeutic Environment

10.1 Fall Prevention Interventions 10.2 Restraint Alternatives, Infection Control & Skin Integrity 10.3 Therapeutic Environment & Milieu Management 10.4 Wound Care Essentials for Older Adults

11 Care Coordination Across the Continuum

11.1 Transitions of Care 11.2 Case Management & Community Resources 11.3 Caregiver Support Systems

12 Theories, Prevention & Health Promotion

12.1 Theoretical Frameworks in Gerontology 12.2 Disease Prevention & Screenings 12.3 Immunizations & Preventive Care for Older Adults 12.4 Self-Management & Health Promotion Strategies

13 Communication & Adult Learning

13.1 Principles of Adult Learning 13.2 Communication Barriers & Adaptations 13.3 Patient & Family Education

14 Diversity, Ethics & Legal Practice

14.1 DEI & Older-Adult Subpopulations 14.2 Advance Directives & Surrogate Decision-Making 14.3 Ethics, Advocacy & Scope of Practice 14.4 Capacity & Informed Consent

15 Regulation, QI & Technology

15.1 CMS & Regulatory Compliance 15.2 Quality Improvement in Gerontological Settings 15.3 EHR & Documentation Standards 15.4 Telehealth, Remote Monitoring & Hospital-at-Home

4.3 Pharmacokinetic Changes with Aging

Key Takeaways Explain This Topic AI

Absorption changes with aging are usually modest; distribution, hepatic metabolism, and especially renal excretion drive most dosing risk

Increased body fat prolongs half-life of lipophilic drugs (e.g., many benzodiazepines); decreased total body water raises concentrations of hydrophilic drugs

Lower serum albumin increases free fraction of highly protein-bound drugs such as phenytoin and warfarin

Hepatic blood flow and Phase I (CYP) metabolism often decline; Phase II conjugation is relatively preserved

Renal clearance falls with age; estimate CrCl (e.g., Cockcroft–Gault) rather than relying on serum creatinine alone

Last updated: August 2026

Pharmacokinetics vs. Pharmacodynamics in Aging

Pharmacokinetics (PK) describes what the body does to the drug: absorption, distribution, metabolism, and excretion (ADME). Pharmacodynamics (PD) describes what the drug does to the body (receptor sensitivity, homeostatic reserve). Both change with aging; this section focuses on PK changes that reshape assessment findings—unexpected toxicity at “usual” doses, delayed clearance after a drug is stopped, and lab misinterpretation.

GERO-BC assessment uses PK aging knowledge to explain why an older adult becomes sedated on a standard benzodiazepine dose, accumulates digoxin with a “normal” creatinine, or shows higher free phenytoin effect when albumin is low.

Absorption

Age-related GI changes include reduced gastric acid in some older adults, delayed gastric emptying, reduced GI motility, and decreased splanchnic blood flow. For most oral drugs, extent of absorption (bioavailability) changes little . Clinically important absorption issues in assessment are more often:

  • Concurrent binders (calcium, iron, antacids, tube-feed interactions)
  • Swallowing impairment and crushed/opened formulations altering release characteristics

First-pass reduction for some high-extraction drugs when hepatic blood flow falls (raising oral bioavailability)

Assessment implication: Do not attribute most toxicity to “poor absorption with age.” Look first at distribution, metabolism, excretion, adherence, and interactions. Ask about timing with supplements and meals when levels are unexpectedly low (e.g., levothyroxine, bisphosphonates, quinolones).

Distribution

Body composition shifts are high-yield:

Aging change PK effect Clinical implication

↑ Body fat ↑ Volume of distribution (Vd) for lipophilic drugs Longer half-life; prolonged sedation after stopping (e.g., diazepam, many benzodiazepines)

↓ Total body water ↓ Vd for hydrophilic drugs Higher plasma concentrations (e.g., digoxin, lithium, aminoglycosides)

↓ Lean muscle mass Alters Vd and creatinine generation Affects dosing weight and renal estimates

↓ Serum albumin ↑ Free (unbound) fraction of highly bound acidic drugs Greater effect/toxicity risk for phenytoin, warfarin, valproate, NSAIDs at same total level

Albumin and free drug

Malnutrition, frailty, liver disease, and acute illness lower albumin. For highly protein-bound drugs, total serum levels can look “therapeutic” while free drug is high . Assessment pairs drug effect (nystagmus, bleeding, sedation) with nutritional status—not the lab number alone.

Loading doses vs. maintenance

Increased Vd for lipophilic drugs may affect loading concepts in acute care, but chronic outpatient toxicity more often reflects reduced clearance and accumulation. For hydrophilic narrow-index drugs, smaller Vd plus reduced renal clearance is a double hazard.

Metabolism (Hepatic)

Hepatic mass and blood flow decline with age. Two metabolic pathways matter conceptually:

Phase I (oxidation/reduction/hydrolysis, largely CYP450): often reduced → higher exposure to parent drug for many agents

Phase II (conjugation: glucuronidation, sulfation, acetylation): relatively preserved → drugs relying mainly on Phase II may be preferable when choices exist (classic teaching example: lorazepam vs. more oxidatively metabolized benzodiazepines)

First-pass metabolism can decrease for some oral drugs, increasing bioavailability. Concurrent CYP inhibitors (macrolides, azoles, amiodarone) magnify age-related metabolic vulnerability.

Assessment implication: New confusion or bradycardia after adding a CYP inhibitor to a previously tolerated regimen suggests accumulation. Chronic liver disease plus advanced age compounds risk.

Excretion (Renal)

Renal excretion is the most clinically important PK change in older adults. Glomerular filtration rate declines with age even when serum creatinine appears “normal,” because lower muscle mass reduces creatinine production.

Estimating kidney function

Prefer estimated creatinine clearance (CrCl) (commonly Cockcroft–Gault for many drug labels) or validated eGFR tools as appropriate to the drug and setting

  • Never assume normal renal clearance from a serum creatinine of 0.8–1.0 mg/dL in a thin older adult
  • Acute illness, dehydration, and NSAIDs can abruptly worsen clearance

Drugs that commonly need renal-aware assessment include digoxin, lithium, many antibiotics (aminoglycosides, vancomycin, some fluoroquinolones), DOACs (agent-specific), gabapentin/pregabalin, H2 blockers, and atenolol. Accumulation presents as CNS depression, bradycardia, bleeding, or myoclonus depending on the agent.

  • Parameter Typical aging trend Assessment takeaway
  • Absorption extent Minimal change for most drugs Focus on binders, formulation, first-pass exceptions
  • Body fat Increases Lipophilic drugs linger
  • Body water / muscle Decreases Hydrophilic drugs concentrate; creatinine misleads
  • Albumin Often decreases in frailty ↑ free fraction of bound drugs
  • Phase I metabolism Often decreases Higher exposure; inhibitor interactions riskier
  • Phase II metabolism Relatively preserved Conceptual advantage for some agents
  • Renal clearance Decreases Estimate CrCl; adjust interpretation of “standard” doses
  • Linking PK Changes to Assessment Findings

Use PK reasoning at the bedside:

  • Prolonged sedation days after last benzodiazepine dose → lipophilic distribution + reduced clearance
  • Digoxin toxicity with “normal” creatinine → low muscle mass hiding reduced GFR + ↓ body water

Bleeding on stable warfarin dose during acute illness with low albumin → higher free fraction + interacting drugs/diet changes

  • Gabapentin-related myoclonus or sedation after dehydration → renal accumulation
  • Level-effect mismatch for phenytoin → interpret free levels / albumin context
  • Frailty and reserve

PK changes interact with PD sensitivity (greater CNS depression from sedatives, blunted baroreflexes with antihypertensives). Assessment documents both the drug exposure story and the functional consequence—falls, delirium, syncope—so the team can adjust therapy.

Exam tip: Memorize the directional map—↑ fat, ↓ water, ↓ albumin, ↓ Phase I, ↓ renal clearance—and practice applying it to lipophilic sedatives, hydrophilic narrow-index drugs, and creatinine misinterpretation. Absorption is rarely the main aging villain on GERO-BC items.